

USANA HEALTH SCIENCES INC  
Form 10-Q  
November 06, 2014  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 27, 2014

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number: 001-35024

---

**USANA HEALTH SCIENCES, INC.**

(Exact name of registrant as specified in its charter)

**Utah**  
(State or other jurisdiction  
of incorporation or organization)

**87-0500306**  
(I.R.S. Employer  
Identification No.)

---

**3838 West Parkway Blvd., Salt Lake City, Utah 84120**

(Address of principal executive offices, Zip Code)

---

**(801) 954-7100**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer   
Non-accelerated filer

Accelerated filer   
Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

The number of shares outstanding of the registrant's common stock as of November 3, 2014 was 12,314,038.

---

Table of Contents

USANA HEALTH SCIENCES, INC.

FORM 10-Q

For the Quarterly Period Ended September 27, 2014

INDEX

	Page
<b><u>PART I. FINANCIAL INFORMATION</u></b>	
<u>Item 1</u>	
<u>Financial Statements (unaudited)</u>	
<u>Condensed Consolidated Balance Sheets</u>	3
<u>Condensed Consolidated Statements of Comprehensive Income</u>	4
<u>Condensed Consolidated Statements of Stockholders' Equity</u>	5
<u>Condensed Consolidated Statements of Cash Flows</u>	6
<u>Notes to Condensed Consolidated Financial Statements</u>	7-15
<u>Item 2</u>	
<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	16-25
<u>Item 3</u>	
<u>Quantitative and Qualitative Disclosures About Market Risk</u>	25
<u>Item 4</u>	
<u>Controls and Procedures</u>	26
<b><u>PART II. OTHER INFORMATION</u></b>	
<u>Item 1</u>	
<u>Legal Proceedings</u>	27
<u>Item 2</u>	
<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	28
<u>Item 6</u>	
<u>Exhibits</u>	29-30
<u>Signatures</u>	31

Table of Contents**PART I. FINANCIAL INFORMATION****Item 1. Financial Statements****USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES****CONDENSED CONSOLIDATED BALANCE SHEETS**

(in thousands, except par value)

(unaudited)

	As of December 28, 2013	As of September 27, 2014
<b>ASSETS</b>		
Current assets		
Cash and cash equivalents	\$ 137,343	\$ 87,738
Securities held-to-maturity, net	8,642	
Inventories	47,242	42,584
Prepaid expenses and other current assets	35,818	32,190
Total current assets	229,045	162,512
Property and equipment, net	59,180	66,310
Goodwill	18,243	18,092
Intangible assets, net	42,329	41,482
Deferred tax assets	5,519	5,597
Other assets	14,154	22,937
	\$ 368,470	\$ 316,930
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities		
Accounts payable	\$ 9,502	\$ 6,551
Line of credit - short term		10,000
Other current liabilities	86,369	88,912
Total current liabilities	95,871	105,463
Deferred tax liabilities	10,866	10,763
Other long-term liabilities	1,211	1,256
Stockholders' equity	14	12

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Common stock, \$0.001 par value; Authorized 50,000 shares, issued and outstanding 13,886  
as of December 28, 2013 and 12,370 as of September 27, 2014

Additional paid-in capital	54,691	38,597
Retained earnings	200,023	155,656
Accumulated other comprehensive income	5,794	5,183
Total stockholders' equity	260,522	199,448
	\$ 368,470	\$ 316,930

The accompanying notes are an integral part of these statements.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands, except per share data)

(unaudited)

	Quarter Ended		Nine Months Ended	
	September 28, 2013	September 27, 2014	September 28, 2013	September 27, 2014
Net sales	\$ 173,691	\$ 191,944	\$ 531,909	\$ 562,601
Cost of sales	31,491	34,585	93,657	103,278
Gross profit	142,200	157,359	438,252	459,323
Operating expenses:				
Associate incentives	76,361	82,605	224,017	242,577
Selling, general and administrative	41,145	45,499	126,527	133,282
Total operating expenses	117,506	128,104	350,544	375,859
Earnings from operations	24,694	29,255	87,708	83,464
Other income (expense):				
Interest income	119	8	278	435
Interest expense		(5)		(11)
Other, net	(43)	(300)	(311)	(299)
Other income (expense), net	76	(297)	(33)	125
Earnings before income taxes	24,770	28,958	87,675	83,589
Income taxes	8,017	9,460	28,933	28,253
Net earnings	\$ 16,753	\$ 19,498	\$ 58,742	\$ 55,336
Earnings per common share				
Basic	\$ 1.22	\$ 1.51	\$ 4.31	\$ 4.09
Diluted	\$ 1.16	\$ 1.47	\$ 4.16	\$ 3.96
Weighted average common shares outstanding				
Basic	13,751	12,873	13,636	13,520
Diluted	14,393	13,263	14,132	13,964
Comprehensive income:				
Net earnings	\$ 16,753	\$ 19,498	\$ 58,742	\$ 55,336

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Other comprehensive income (loss), net of tax:							
Foreign currency translation adjustment	1,371		(198)		(1,070)		(1,058)
Tax benefit (expense) related to foreign currency translation adjustment	(552)		57		180		447
Other comprehensive income (loss), net of tax	819		(141)		(890)		(611)
Comprehensive income	\$	17,572	\$	19,357	\$	57,852	\$ 54,725

The accompanying notes are an integral part of these statements.



Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY

Nine Months Ended September 27, 2014

(in thousands)

(unaudited)

	Common Stock Shares	Common Stock Value	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total
Balance at December 28, 2013	13,886	\$ 14	\$ 54,691	\$ 200,023	\$ 5,794	\$ 260,522
Net earnings				55,336		55,336
Other comprehensive income (loss), net of tax					(611)	(611)
Equity-based compensation expense			5,929			5,929
Common stock repurchased and retired	(1,755)	(2)	(25,947)	(99,703)		(125,652)
Common stock issued under equity award plans, including tax benefit of \$3,924	239		3,924			3,924
Balance at September 27, 2014	12,370	\$ 12	\$ 38,597	\$ 155,656	\$ 5,183	\$ 199,448

The accompanying notes are an integral part of these statements.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

	Nine Months Ended	
	September 28, 2013	September 27, 2014
Cash flows from operating activities		
Net earnings	\$ 58,742	\$ 55,336
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities		
Depreciation and amortization	6,870	6,685
(Gain) loss on sale of property and equipment	(23)	31
Equity-based compensation expense	6,113	5,929
Excess tax benefits from equity-based payment arrangements	(7,570)	(3,996)
Deferred income taxes	1,196	(849)
Changes in operating assets and liabilities:		
Inventories	(9,999)	4,956
Prepaid expenses and other assets	(9,153)	(524)
Accounts payable	1,048	(3,249)
Other liabilities	17,369	3,076
Net cash provided by (used in) operating activities	64,593	67,395
Cash flows from investing activities		
Additions to notes receivable	(3,363)	(3,159)
Purchases of investment securities held-to-maturity		(3,871)
Maturities of investment securities		12,511
Proceeds from sale of property and equipment	47	10
Purchases of property and equipment	(6,306)	(13,266)
Net cash provided by (used in) investing activities	(9,622)	(7,775)
Cash flows from financing activities		
Proceeds from equity awards exercised	454	
Excess tax benefits from equity-based payment arrangements	7,570	3,996
Repurchase of common stock	(18,085)	(122,662)
Borrowings on line of credit		10,000
Net cash provided by (used in) financing activities	(10,061)	(108,666)
Effect of exchange rate changes on cash and cash equivalents	(400)	(559)
Net increase (decrease) in cash and cash equivalents	44,510	(49,605)

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Cash and cash equivalents, beginning of period		70,839		137,343
Cash and cash equivalents, end of period	\$	115,349	\$	87,738
Supplemental disclosures of cash flow information				
Cash paid during the period for:				
Interest	\$		\$	11
Income taxes		25,554		11,716
Non-cash financing activities:				
Unsettled trades for repurchase of common stock				(2,990)

The accompanying notes are an integral part of these statements

Table of Contents

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(in thousands, except per share data)**

**(unaudited)**

**NOTE A ORGANIZATION, CONSOLIDATION, AND BASIS OF PRESENTATION**

USANA Health Sciences, Inc. develops and manufactures high-quality nutritional and personal care products that are sold internationally through a global network marketing system, which is a form of direct selling. The Consolidated Financial Statements include the accounts and operations of USANA Health Sciences, Inc. and its wholly-owned subsidiaries (collectively, the Company or USANA ) in two geographic regions: Americas and Europe, and Asia Pacific, which is further divided into three sub-regions; Southeast Asia Pacific, Greater China, and North Asia. Americas and Europe includes the United States, Canada, Mexico, Colombia, the United Kingdom, France, Belgium, and the Netherlands. Southeast Asia Pacific includes Australia, New Zealand, Singapore, Malaysia, the Philippines, and Thailand; Greater China includes Hong Kong, Taiwan and China; and North Asia includes Japan and South Korea. All significant intercompany accounts and transactions have been eliminated in this consolidation.

The condensed consolidated balance sheet as of December 28, 2013, derived from audited financial statements, and the unaudited interim consolidated financial information of the Company have been prepared in accordance with Article 10 of Regulation S-X promulgated by the Securities and Exchange Commission. Certain information and footnote disclosures that are normally included in financial statements that have been prepared in accordance with accounting principles generally accepted in the United States of America ( U.S. GAAP ) have been condensed or omitted pursuant to such rules and regulations. The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and the disclosure of any contingent amounts in our condensed consolidated financial statements and accompanying notes. Actual results could differ from these estimates. In the opinion of management, the accompanying interim consolidated financial information contains all adjustments, consisting of normal recurring adjustments that are necessary to state fairly the Company's financial position as of September 27, 2014 and results of operations for the quarters and nine months ended September 28, 2013 and September 27, 2014.

The interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto that are included in the Company's Annual Report on Form 10-K for the year ended December 28, 2013. The results of operations for the quarter and nine months ended September 27, 2014, may not be indicative of the results that may be expected for the fiscal year 2014 ending January 3, 2015.

The Company experienced a change in the trend of the aging of unearned revenue in Hong Kong resulting from worldwide policy changes implemented in 2013. As a result of this change in trend, during the quarter ended September 27, 2014, the Company concluded that it was remote that product orders older than two years would be picked up by the customer. Deferred revenue of \$3,100 recognized in the current quarter from this change in estimate benefited net earnings by \$1,400.

**Recent Accounting Pronouncements**

In May 2014, the Financial Accounting Standards Board ( FASB ) issued an Accounting Standard Update ( ASU ) No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 includes a five-step process by which entities will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which an entity expects to be entitled to in exchange for those goods or services. The standard also will require enhanced disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for annual and interim reporting periods beginning after December 15, 2016, with early adoption prohibited. Accordingly, the Company will adopt this ASU on January 1, 2017. ASU 2014-09 permits companies the use of either a full retrospective or a modified retrospective approach to adopt this ASU, and the Company is currently evaluating which transition approach to use. The Company is currently evaluating the impact ASU 2014-09 will have on its consolidated financial statements.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

(unaudited)

## NOTE B FAIR VALUE MEASURES

The Company measures at fair value certain of its financial and non-financial assets and liabilities by using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price, based on the highest and best use of the asset or liability. The levels of the fair value hierarchy are:

- Level 1 inputs are quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement date.
- Level 2 inputs are from other than quoted market prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3 inputs are unobservable and are used to measure fair value in situations where there is little, if any, market activity for the asset or liability at the measurement date.

As of December 28, 2013 and September 27, 2014, the following financial assets and liabilities were measured at fair value on a recurring basis using the type of inputs shown:

	December 28, 2013		Fair Value Measurements Using:		
			Level 1 Inputs	Level 2 Inputs	Level 3 Inputs
Money market funds included in cash equivalents	\$ 9,249	\$ 9,249			\$
Term deposits included in cash equivalents	348			348	
	September 27, 2014		Fair Value Measurements Using:		
			Level 1 Inputs	Level 2 Inputs	Level 3 Inputs
Money market funds included in cash equivalents	\$ 13,872	\$ 13,872			\$

There were no transfers of financial assets or liabilities between Level 1 and Level 2 inputs for the periods indicated.

The majority of the Company's non-financial assets, which include goodwill, intangible assets, and property and equipment, are not required to be carried at fair value on a recurring basis. However, if certain triggering events occur (or tested at least annually for goodwill and indefinite-lived intangibles) such that a non-financial asset is required to be evaluated for impairment, an impairment is recorded to reduce the carrying value to the fair value, if the carrying value exceeds the fair value. At December 28, 2013 and September 27, 2014, there were no non-financial assets measured at fair value on a non-recurring basis.

The Company's financial instruments include cash equivalents, restricted cash, securities held-to-maturity ( HTM ), and notes receivable. The recorded values of cash equivalents and restricted cash approximate their fair values, based on their short-term nature. The carrying value of the notes receivable approximate fair value because the variable interest rates in the notes reflect current market rates (see Note F). HTM securities consist of certificates of deposits. The fair value of a certificate of deposit is determined based on the pervasive interest rates in the market, which is considered to be a Level 2 input. The carrying values of these certificates of deposit approximate their fair values due to their short-term maturities.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

(unaudited)

## NOTE C INVESTMENTS

The carrying amount, gross unrealized holding gains, gross unrealized holding losses, and fair value of HTM securities by major security type and class of security were as follows:

		As of December 28, 2013		
	Amortized Cost	Unrecognized Holding Gains	Unrecognized Holding Losses	Estimated Fair Value
Certificates of Deposit	\$ 8,642	\$	\$	\$ 8,642
Total HTM Securities	\$ 8,642	\$	\$	\$ 8,642

As of September 27, 2014, all HTM securities had matured and there was no balance.

## NOTE D INVENTORIES

Inventories consist of the following:

	December 28, 2013	September 27, 2014
Raw materials	\$ 13,824	\$ 12,745
Work in progress	8,147	7,970
Finished goods	25,271	21,869
	\$ 47,242	\$ 42,584

## NOTE E INTANGIBLE ASSETS



## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

The Company performed its annual goodwill impairment test during the third quarter of 2014. The Company performed a qualitative assessment of each reporting unit and determined that it was not more-likely-than-not that the fair value of each reporting unit was less than its carrying amount. As a result, the two-step goodwill impairment test was not required and no impairments of goodwill were recognized.

The Company performed its annual indefinite-lived intangible asset impairment test during the third quarter of 2014. The Company performed a qualitative assessment of the indefinite-lived intangible assets and determined that it was not more-likely-than-not that the fair value of the indefinite-lived intangible assets was less than the carrying amount. As a result, the quantitative impairment test was not required and no impairments of indefinite-lived intangible assets were recognized.

### **NOTE F OTHER ASSETS**

The Company has extended non-revolving credit to its supplier of nutrition bars to allow this supplier to acquire the necessary equipment to manufacture the USANA nutrition bars. Notes receivable are valued at their unpaid principal balance plus any accrued but unpaid interest, which approximates fair value. Interest accrues at an annual interest rate of LIBOR plus 400 basis points. The note has a maturity date of February 1, 2024 and will be repaid by a combination of cash payments and credits for the manufacture of USANA's nutrition bars. There is no prepayment penalty. Notes receivable from this supplier as of December 28, 2013, and September 27, 2014 were \$4,942 and \$7,359, respectively.

Table of Contents

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(in thousands, except per share data)**

**(unaudited)**

**NOTE F OTHER ASSETS CONTINUED**

The Company is in the process of evaluating options to potentially modify some of the terms of the credit agreement with its supplier of nutrition bars as there has been a delay in the completion of the project. As a result of the delays, the Company performed an impairment test on the recoverability of the note receivable which required the use of estimates and assumptions. The Company concluded that there was no impairment as of September 27, 2014, however, if assumptions change in the future, impairment charges could result. The Company will continue to evaluate the note receivable for impairment at each reporting period.

The Company is building a state-of-the-art manufacturing and production facility in China, which is expected to become operational during the latter half of 2015. As part of this project, land use rights totaling \$1,483, and \$7,474 as of December 28, 2013 and September 27, 2014, respectively, have been purchased and will be amortized over 50 years. Land-use rights are classified within the Other assets line item in the Company's consolidated balance sheets.

**NOTE G LINE OF CREDIT**

The Company has a \$75,000 line of credit with Bank of America. Interest is computed at the bank's Prime Rate or LIBOR, adjusted by features specified in the Credit Agreement. The collateral for this line of credit is the pledge of the capital stock of certain subsidiaries of the Company, set forth in a separate pledge agreement with the bank. Part of the credit agreement is that any existing bank guarantees are considered a reduction of the overall availability of credit and part of the covenant calculation. This resulted in a \$3,800, and \$4,719 reduction in the available borrowing limit as of December 28, 2013 and September 27, 2014, respectively, due to existing normal course of business guarantees in certain markets. The Credit Agreement contains restrictive covenants based on adjusted EBITDA and a debt coverage ratio.

There was no outstanding debt on this line of credit at December 28, 2013. At September 27, 2014, there was an outstanding balance of \$10,000. The Company will be required to pay any balance on this line of credit in full at the time of maturity in April 2016 unless the line of credit is replaced or terms are renegotiated. This balance is classified as a current liability due to the Company's intent to pay the balance within the next 12 months.

**NOTE H CONTINGENCIES**

## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. While complete assurance cannot be given to the outcome of these proceedings, management does not currently believe that any of these matters, individually or in the aggregate, will have a material adverse effect on our financial condition, liquidity or results of operations.

On August 7, 2014, a purported shareholder derivative lawsuit was filed in the Third Judicial District Court of Salt Lake County, State of Utah, against certain of the Company's directors and officers. The derivative complaint, which also names USANA as a nominal defendant but is asserted on USANA's behalf, contains claims of breach of fiduciary duty, waste of corporate assets and unjust enrichment against the defendant directors and officers in connection with certain equity awards granted by the Compensation Committee of the Company's Board of Directors in February 2014. The Company believes the claims in the complaint are without merit and intends to vigorously defend the suit. In the opinion of management, and based upon advice of counsel, the likelihood of an adverse outcome against the Company in this matter is remote. As such, management believes that the ultimate outcome of this lawsuit will not have a material impact on the Company's financial position or results of operations.

Table of Contents

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(in thousands, except per share data)**

**(unaudited)**

**NOTE I EQUITY BASED COMPENSATION**

The Company utilizes a share-based compensation plan, which is more fully described in Note K to the Consolidated Financial Statements in Form 10-K for the year ended December 28, 2013.

Equity-based compensation expense for the fiscal quarters ended September 28, 2013, and September 27, 2014, was \$1,686, and \$1,858 respectively. The related tax benefit for these periods was \$578, and \$613, respectively. Expense for the nine months ended September 28, 2013, and September 27, 2014, was \$6,113 and \$5,929, respectively. The related tax benefit for these periods was \$2,087 and \$1,973, respectively.

The following table shows the remaining unrecognized compensation expense on a pre-tax basis for all types of unvested equity awards outstanding as of September 27, 2014. This table does not include an estimate for future grants that may be issued.

2014	\$	2,388
2015		7,388
2016		5,622
2017		3,516
2018+		724
	\$	19,638

The cost above is expected to be recognized over a weighted-average period of 2.0 years.

The Company uses the Black-Scholes option pricing model to estimate the fair value of its equity awards. The weighted-average fair value of stock-settled stock appreciation rights that were granted during the nine months ended September 28, 2013, and September 27, 2014, was \$16.01 and \$17.92, respectively. Following is a table that includes the weighted-average assumptions that the Company used to calculate fair value of equity awards that were granted during the periods indicated.

<b>Nine Months Ended</b>	
<b>September 28,</b>	<b>September 27,</b>
<b>2013</b>	<b>2014</b>

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Expected volatility (1)	42.5%	40.0%
Risk-free interest rate (2)	0.7%	1.2%
Expected life (3)	3.95yrs	3.55yrs
Expected dividend yield (4)	0.0%	0.0%
Weighted-average exercise price (5)	\$ 48.26	\$ 58.04

---

(1) The Company utilizes historical volatility of the trading price of its common stock.

(2) Risk-free interest rate is based on the U.S. Treasury yield curve with respect to the expected life of the award.

(3) Depending upon the terms of the award, one of two methods will be used to calculate expected life: (i) a weighted-average that includes historical settlement data of the Company's equity awards and a hypothetical holding period, or (ii) the simplified method.

(4) The Company historically has not paid dividends.

(5) Exercise price is the closing price of the Company's common stock on the date of grant.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

(unaudited)

## NOTE I EQUITY BASED COMPENSATION - CONTINUED

A summary of the Company's stock option and stock-settled stock appreciation right activity is as follows:

	Shares	Weighted- average exercise price	Weighted-average remaining contractual term	Aggregate intrinsic value*
Outstanding at December 28, 2013	1,827	\$ 37.37	2.6	\$ 74,160
Granted	711	58.04		
Exercised	(434)	32.33		
Forfeited	(48)	37.25		
Expired				
Outstanding at September 27, 2014	2,056	\$ 45.58	2.7	\$ 54,978
Exercisable at September 27, 2014	526	\$ 38.37	1.4	\$ 17,743

\* Aggregate intrinsic value is defined as the difference between the current market value at the reporting date (the closing price of the Company's common stock on the last trading day of the period) and the exercise price of awards that were in-the-money. The closing price of the Company's common stock at December 28, 2013, and September 27, 2014, was \$77.72 and \$71.98, respectively.

The total intrinsic value of stock options and stock-settled stock appreciation rights exercised during the nine months ended September 28, 2013, and September 27, 2014, was \$31,027 and \$17,125, respectively.

The total fair value of equity awards that vested during the nine months ended September 28, 2013, and September 27, 2014, was \$6,789 and \$6,559, respectively. This total fair value includes equity-based awards issued in the form of stock options and stock-settled stock appreciation rights.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

(unaudited)

## NOTE J COMMON STOCK AND EARNINGS PER SHARE

Basic earnings per share are based on the weighted-average number of shares outstanding for each period. Shares that have been repurchased and retired during the periods specified below have been included in the calculation of the number of weighted-average shares that are outstanding for the calculation of basic earnings per share based on the time they were outstanding in any period. Diluted earnings per common share are based on shares that are outstanding (computed under basic EPS) and on potentially dilutive shares. Shares that are included in the diluted earnings per share calculations under the treasury stock method include equity awards that are in-the-money but have not yet been exercised.

The following is a reconciliation of the numerator and denominator used to calculate basic earnings per share and diluted earnings per share for the periods indicated:

	Quarter Ended		Nine Months Ended	
	September 28, 2013	September 27, 2014	September 28, 2013	September 27, 2014
Net earnings available to common shareholders	\$ 16,753	\$ 19,498	\$ 58,742	\$ 55,336
Weighted average common shares outstanding - basic	13,751	12,873	13,636	13,520
Dilutive effect of in-the-money equity awards	642	390	496	444
Weighted average common shares outstanding - diluted	14,393	13,263	14,132	13,964
Earnings per common share from net earnings - basic	\$ 1.22	\$ 1.51	\$ 4.31	\$ 4.09
Earnings per common share from net earnings - diluted	\$ 1.16	\$ 1.47	\$ 4.16	\$ 3.96

Equity awards for the following shares were not included in the computation of diluted EPS due to the fact that their effect would be anti-dilutive:

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

	Quarter Ended		Nine Months Ended	
	September 28, 2013	September 27, 2014	September 28, 2013	September 27, 2014
	15	414	445	357

During the quarter ended September 27, 2014, the Company repurchased and retired 1,073 shares, for \$76,558 under the Company's share repurchase plan.

During the nine months ended September 28, 2013, and September 27, 2014, the Company repurchased and retired 414 shares and 1,755 shares, for \$18,085 and \$125,652, respectively, under the Company's share repurchase plan. The excess of the repurchase price over par value is allocated between additional paid-in capital and retained earnings on a pro-rata basis. The purchase of shares under this plan reduces the number of shares outstanding in the above calculations.

Subsequent to the period ended September 27, 2014 and through November 3, 2014, the Company repurchased and retired 172 shares under the Company's share repurchase plan for a total of \$13,167. As of November 3, 2014, the remaining approved repurchase amount under the plan was \$61,181.



Table of Contents**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(in thousands, except per share data)****(unaudited)****NOTE K SEGMENT INFORMATION**

USANA operates as a direct selling company that develops, manufactures, and distributes high-quality nutritional and personal care products that are sold through a global network marketing system of independent distributors ( Associates ). As such, management aggregates its operating segments into one reportable segment as management believes that the Company's segments exhibit similar long-term financial performance and have similar economic characteristics. Performance for a region or market is evaluated based on sales. No single Associate accounted for 10% or more of net sales for the periods presented. The table below summarizes the approximate percentage of total product revenue that has been contributed by the Company's nutritional and personal care products for the periods indicated.

	Quarter Ended		Nine Months Ended	
	September 28, 2013	September 27, 2014	September 28, 2013	September 27, 2014
USANA® Nutritionals	79%	78%	80%	79%
USANA Foods	13%	13%	12%	13%
Sensé beautiful science®	6%	7%	6%	7%

Selected financial information for the Company is presented for two geographic regions: Americas and Europe, and Asia Pacific, with three sub-regions under Asia Pacific. Individual markets are categorized into these regions as follows:

- Americas and Europe United States, Canada, Mexico, Colombia (1), the United Kingdom, France, Belgium, and the Netherlands.
- Asia Pacific
- Southeast Asia Pacific Australia, New Zealand, Singapore, Malaysia, the Philippines, and Thailand
- Greater China Hong Kong, Taiwan and China(2)

- North Asia Japan and South Korea

---

(1) The Company commenced operations in Colombia in the third quarter of 2013.

(2) The Company's business in China is that of BabyCare, its wholly-owned subsidiary.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

(unaudited)

## NOTE K SEGMENT INFORMATION - CONTINUED

*Selected Financial Information*

Financial information by geographic region is presented for the periods indicated below:

	Quarter Ended		Nine Months Ended	
	September 28, 2013	September 27, 2014	September 28, 2013	September 27, 2014
Net Sales to External Customers				
Americas and Europe	\$ 66,294	\$ 61,723	\$ 197,215	\$ 189,199
Asia Pacific				
Southeast Asia Pacific	40,230	44,488	113,014	127,625
Greater China	59,768	77,206	200,141	222,144
North Asia	7,399	8,527	21,539	23,633
Asia Pacific Total	107,397	130,221	334,694	373,402
Consolidated Total	\$ 173,691	\$ 191,944	\$ 531,909	\$ 562,601

The following table provides further information on markets representing ten percent or more of consolidated net sales and long-lived assets, respectively:

	Quarter Ended		Nine Months Ended	
	September 28, 2013	September 27, 2014	September 28, 2013	September 27, 2014
Net sales:				
China	\$ 29,788	\$ 50,385	\$ 66,772	\$ 140,368
United States	39,282	34,389	118,329	105,938
Hong Kong	21,554	NA	109,089	57,686

As of

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

	December 28, 2013	September 27, 2014
Long-lived Assets:		
China	\$ 61,716	\$ 75,940
United States	51,260	52,586

Table of Contents

**Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

The following discussion and analysis of USANA's financial condition and results of operations is presented in six sections:

- Overview
- Customers
- Current Focus and Recent Developments
- Results of Operations
- Liquidity and Capital Resources
- Forward-Looking Statements and Certain Risks

This discussion and analysis should be read in conjunction with the Unaudited Condensed Consolidated Financial Statements and Notes thereto that are contained in this quarterly report, as well as Management's Discussion and Analysis of Financial Condition and Results of Operations that are included in our Annual Report on Form 10-K for the year ended December 28, 2013, and our other filings, including Current Reports on Form 8-K, that have been filed with the Securities and Exchange Commission (SEC) through the date of this report.

**Overview**

We develop and manufacture high-quality, science-based nutritional and personal care products that are distributed internationally through a network marketing system, which is a form of direct selling. We have chosen this distribution method as we believe it is more conducive to meeting our vision as a company, which is improving the overall health and nutrition of individuals and families around the world. Our customer base comprises two types of customers: Associates and Preferred Customers. Associates share in our company vision by acting as independent distributors of our products in addition to purchasing our products for their personal use. Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. As of September 27, 2014, we had approximately 291,000 active Associates and approximately 77,000 active Preferred Customers worldwide. For purposes of this report, we only count as active customers those Associates and Preferred Customers who have purchased from us at any time during the most recent three-month period.

We have ongoing operations in the following markets, which are grouped and presented as follows:

- Americas and Europe United States, Canada, Mexico, Colombia(1), the United Kingdom, France, Belgium, and the Netherlands

- Asia Pacific
  
- Southeast Asia Pacific Australia, New Zealand, Singapore, Malaysia, the Philippines, and Thailand
  
- Greater China Hong Kong, Taiwan, and China(2)
  
- North Asia Japan and South Korea

- 
- (1) We commenced operations in Colombia in the third quarter of 2013.
  - (2) Our business in China is that of BabyCare, our wholly-owned subsidiary.

Our primary product lines consist of USANA® Nutritionals, USANA Foods, and Sensé beautiful science® (Sensé), which is our line of personal care products. The USANA Nutritionals product line is further categorized into two separate classifications: Essentials and Optimizers. The following tables summarize the approximate percentage of total product revenue that has been contributed by our major product lines and our top-selling products for the current and prior-year periods as indicated:

Table of Contents

<b>Product Line</b>	<b>Nine Months Ended</b>	
	<b>September 28, 2013</b>	<b>September 27, 2014</b>
USANA® Nutritionals		
Essentials	27%	25%
Optimizers	53%	54%
USANA Foods	12%	13%
Sensé beautiful science®	6%	7%
All Other	2%	1%
<b>Key Product</b>		
USANA® Essentials	18%	16%
Proflavanol®	12%	13%

We believe that our ability to attract and retain Associates and Preferred Customers to sell and consume our products is positively influenced by a number of factors, some of which include: the general public's heightened awareness and understanding of the connection between diet and long-term health, and the growing desire for a secondary source of income and small business ownership.

We believe that our high-quality products and our financially rewarding Associate Compensation Plan are the key components to attracting and retaining Associates. We strive to ensure that our products are formulated with the latest science in nutrition research and to keep our product lines relatively compact, which we believe simplifies the selling and buying process for our Associates and Preferred Customers. We also periodically make changes to our Compensation Plan in an effort to ensure that our plan is among the most rewarding in the industry, to encourage behavior that we believe leads to a successful business for our Associates, and to ensure that our plan provides us with leverage to grow sales and earnings.

To further support our Associates in building their businesses, we sponsor meetings and events throughout the year, which offer information about our products and our network marketing system. These meetings are designed to assist Associates in their business development and to provide a forum for interaction with our Associate leaders and members of our management team. We also provide low cost sales tools, including online sales, business management, and training tools, which we believe are an integral part of building and maintaining a successful home-based business for our Associates. Although we provide training and sales tools, we ultimately rely on our Associates to sell our products, attract new customers to purchase our products, and educate and train new Associates.

Because we have operations in multiple markets, with sales and expenses being generated and incurred in multiple currencies, our reported U.S. dollar sales and earnings can be significantly affected by fluctuations in currency exchange rates. In general, net sales and gross profit are affected positively by a weakening of the U.S. dollar and negatively by a strengthening of the U.S. dollar. Associate incentives and selling, general and administrative expenses, however, are affected negatively by a weakening of the U.S. dollar and positively by a strengthening of the U.S. dollar. During the nine months ended September 27, 2014, net sales outside of the United States represented 80.7% of consolidated net sales. In our net sales discussions that follow, we approximate the impact of currency fluctuations on net sales by translating current year sales at the average exchange rates in effect during the comparable periods of the prior year.

**Customers**

## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Because we sell our products exclusively to a customer base of independent Associates and Preferred Customers, to increase net sales we must either increase the number of, or the productivity of, our Associates and Preferred Customers. Increasing the productivity of our Associates and Preferred Customers has not been our primary focus. Rather, we seek to increase the number of Associates and Preferred Customers who use our products. We believe this focus is more consistent with our vision of improving the overall health and nutrition of individuals and families around the world. Sales to Associates account for the majority of our product sales, representing



Table of Contents

approximately 91% of product sales during the nine months ended September 27, 2014. The remainder of our sales are to Preferred Customers. Increases or decreases in product sales are typically the result of variations in the volume of product sold relating to fluctuations in the number of active Associates and Preferred Customers purchasing our products. The number of active Associates and Preferred Customers is, therefore, used by management as a key non-financial measure.

The tables below summarize the changes in our active customer base by geographic region. These numbers have been rounded to the nearest thousand as of the dates indicated.

Active Associates By Region						
	As of September 28, 2013		As of September 27, 2014		Change from Prior Year	Percent Change
Americas and Europe	82,000	33.5%	82,000	28.2%		0.0%
Asia Pacific:						
Southeast Asia Pacific	60,000	24.4%	70,000	24.1%	10,000	16.7%
Greater China	94,000	38.4%	129,000	44.3%	35,000	37.2%
North Asia	9,000	3.7%	10,000	3.4%	1,000	11.1%
Asia Pacific Total	163,000	66.5%	209,000	71.8%	46,000	28.2%
	245,000	100.0%	291,000	100.0%	46,000	18.8%

Preferred Customers By Region						
	As of September 28, 2013		As of September 27, 2014		Change from Prior Year	Percent Change
Americas and Europe	58,000	81.7%	57,000	74.0%	(1,000)	(1.7)%
Asia Pacific:						
Southeast Asia Pacific	8,000	11.3%	11,000	14.3%	3,000	37.5%
Greater China	3,000	4.2%	3,000	3.9%		0.0%
North Asia	2,000	2.8%	6,000	7.8%	4,000	200.0%
Asia Pacific Total	13,000	18.3%	20,000	26.0%	7,000	53.8%
	71,000	100.0%	77,000	100.0%	6,000	8.5%

**Current Focus and Recent Developments**

As a company, USANA seeks to improve the overall health and nutrition of individuals and families around the world. Consequently, our primary objective is to increase the number of Associates and Preferred Customers who use our products. In August 2014, we held our 2014 International Convention, where we made several improvements to our business, which were designed to improve our customers' experience with USANA. For example, we launched an all new digital marketing suite for our world-wide Associate base. The suite provides our Associates with new tools, consisting of a back office Hub, personal websites, and advanced communication and marketing tools, all of which significantly enhance our Associates' ability to manage, promote and build their USANA business in today's demanding ebusiness environment. These new tools were designed to simplify conducting a USANA business, enhance communications and provide an online atmosphere that is personal to the Associate and highly engaging for the customer.

In August of 2013, we announced and implemented several strategic changes to our business, which we refer to as the 2013 strategic changes throughout this report. These changes were aimed at promoting customer loyalty, enjoyment and success with USANA. The 2013 strategic changes included: (i) simplification of our pricing structure, which included an overall 10% price reduction,

Table of Contents

while maintaining a price discount on products ordered through our monthly Auto Order program (collectively price discounts ), (ii) a new reward based on the amount of a customer's initial product order to then be credited on their subsequent two Auto Orders, and (iii) increased payout under and simplification of our Compensation Plan.

We increased the payout under our Compensation Plan in several ways, including: (i) paying higher compensation to newer Associates, (ii) increasing compensation for Associates who grow their business through our Auto Order program, and (iii) simplifying the commission qualification requirements under the plan, resulting in a greater number of Associates earning compensation. Additionally, we simplified our rank advancement system to make it easier for Associates to advance in our business, and we added new recognition benefits for Associate leaders.

During the third quarter, our overall active customer counts increased by 16.5% on a year-over-year basis, while net sales increased by 10.5%. Net sales growth trailed customer growth during the quarter primarily as a result of the price discounts associated with the 2013 strategic changes. In September 2014, we reached the one-year anniversary of the 2013 strategic changes and we anticipate, going forward, that overall customer growth and net sales growth will be more closely aligned. Moving forward we will continue to promote the benefits of the 2013 strategic changes to our customer base, but will also begin offering market-specific promotions, which are designed to generate additional customer growth around the world.

**Results of Operations**

*Summary of Financial Results*

Net sales for the third quarter of 2014 increased 10.5% to \$191.9 million, an increase of \$18.3 million, compared with the third quarter of 2013. This increase was driven by overall Associate growth of 18.8%, which was generated by our Asia Pacific region. In general, year-over-year changes in sales in the markets within our regions were the result of corresponding changes in the number of our active Associates and Preferred Customers in these markets. Also affecting the year-over-year change in net sales was the recognition of \$3.1 million in unearned revenue in Hong Kong during the current year quarter, without which consolidated net sales would have increased by 8.7%. We experienced a change in the trend of our aging of unearned revenue in Hong Kong resulting from worldwide policy changes implemented in 2013. As a result of this change in trend, during the quarter ended September 27, 2014, we concluded that it was remote that product orders older than two years would be picked up by the customer. Accordingly, deferred revenue of \$3.1 million was recognized in the current quarter.

Net earnings for the third quarter of 2014 increased 16.4% to \$19.5 million, an increase of \$2.7 million, compared with the third quarter of 2013. This increase was the result of an increase in net sales combined with lower relative Associate incentives expense, as discussed further below. Notably, the recognition of deferred revenue discussed above benefited net earnings by \$1.4 million.

Table of Contents**Quarters Ended September 28, 2013 and September 27, 2014***Net Sales*

The following table summarizes the changes in our net sales by geographic region for the quarters ended as of the dates indicated:

	Net Sales by Region (in thousands) Quarter Ended		September 27, 2014	Change from Prior Year	Percent Change
	September 28, 2013				
Americas and Europe	\$ 66,294	38.2%	\$ 61,723	32.2%	\$ (4,571) (6.9)%
<b>Asia Pacific:</b>					
Southeast Asia Pacific	40,230	23.2%	44,488	23.2%	4,258 10.6%
Greater China	59,768	34.4%	77,206	40.2%	17,438 29.2%
North Asia	7,399	4.2%	8,527	4.4%	1,128 15.2%
Asia Pacific Total	107,397	61.8%	130,221	67.8%	22,824 21.3%
	\$ 173,691	100.0%	\$ 191,944	100.0%	\$ 18,253 10.5%

*Americas and Europe:* The decline in net sales in this region was due to a decrease in net sales in the United States and, to a lesser extent, changes in currency exchange rates, which reduced net sales by \$0.9 million. Net sales in the United States decreased \$4.9 million, or 12.5%, due to a decrease in the number of active Associates and Preferred Customers of 9.3% and 10.5%, respectively, combined with pressure from the price discounts associated with the 2013 strategic changes. The decreases in the United States were partially offset by growth in Mexico, where local currency sales increased 11.0% due to continued growth in the number of active Associates and Preferred Customers.

*Asia Pacific:* The increase in net sales in this region was driven by double-digit growth in Associates and net sales in each of the Greater China, Southeast Asia Pacific, and North Asia regions.

The net sales increase in Greater China was the result of a 69.1% increase in net sales in Mainland China, which was partially offset by a sales decrease in Hong Kong despite the recognition of \$3.1 million of unearned revenue discussed above. The changes in net sales in Mainland China and Hong Kong were reflective of changes in the number of active Associates in each of these markets during the quarter.

The net sales increase in Southeast Asia Pacific was driven by local currency sales growth in most markets within this region and an increase in the number of active Associates in nearly every market within the region. Net sales growth in this region, however, trailed customer growth as a result of the price discounts associated with the 2013 strategic changes. The strongest growth in this region came from the Philippines, where net sales increased 31.8% and the number of active Associates increased by 28.0%. While the number of active Associates in Singapore increased by 16.7% during the quarter, net sales decreased by 7.9%. This sales decrease resulted from a year-over-year decrease in sales of our Asia Pacific MyHealthPak, which is sourced from Singapore, as we passed the one year anniversary of when this item started picking up in sales.

*Gross Profit*

Gross profit for the third quarter of 2014 was 82.0% of net sales, and was essentially flat, on a relative basis, compared to the prior year quarter. Year-over-year gross profit benefited from favorable changes in product and market mix as well as the recognition of \$3.1 million in previously unearned revenue in Hong Kong discussed above. These benefits were largely offset by unfavorable currency fluctuations and production inefficiencies.

Table of Contents*Associate Incentives*

Associate incentives decreased to 43.0% of net sales for the third quarter of 2014, from 44.0% for the third quarter of 2013. This decrease was the result of a one-time payout of \$4.5 million in the third quarter of 2013 associated with the 2013 strategic changes and by annual price changes.

*Selling, General and Administrative Expenses*

Relative to net sales, our selling, general and administrative expense was flat when compared with the third quarter of 2013. In absolute terms, our selling, general and administrative expense increased by \$4.4 million. This increase was primarily driven by higher wages and benefits expense and other costs associated with supporting a higher sales base.

*Diluted Earnings Per Share*

Diluted earnings per share increased 26.7% in the third quarter of 2014 when compared with the prior year quarter. This increase was the result of higher net earnings, as discussed above, combined with a lower number of diluted shares outstanding resulting from share repurchases over the last twelve months. Without the recognition of \$3.1 million of previously unearned revenue in Hong Kong discussed above, diluted earnings per share would have increased 17.2%.

**Nine Months Ended September 28, 2013 and September 27, 2014***Net Sales*

The following table summarizes the changes in our net sales by geographic region for the periods ended as of the dates indicated:

	<b>Net Sales by Region (in thousands)</b>				<b>Change from Prior Year</b>	<b>Percent Change</b>
	<b>September 28, 2013</b>		<b>September 27, 2014</b>			
Americas and Europe	\$ 197,215	37.1%	\$ 189,199	33.6%	\$ (8,016)	(4.1)%
Asia Pacific:						
Southeast Asia Pacific	113,014	21.2%	127,625	22.7%	14,611	12.9%
Greater China	200,141	37.6%	222,144	39.5%	22,003	11.0%

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

North Asia	21,539	4.1%	23,633	4.2%	2,094	9.7%
Asia Pacific Total	334,694	62.9%	373,402	66.4%	38,708	11.6%
	\$ 531,909	100.0%	\$ 562,601	100.0%	\$ 30,692	5.8%

*Americas and Europe:* The decline in net sales in this region was due to a decrease in net sales in the United States and to changes in currency exchange rates, which reduced net sales by \$4.2 million. Net sales in the United States decreased \$12.4 million, or 10.5%, due to pressure from price discounts, combined with a decrease in the average number of active Associates and Preferred Customers. The decrease in the United States, however, was partially offset by net sales growth in other markets within the region. Most notably, local currency sales increased 7.3% in Canada and 12.6% in Mexico due to continued growth in the number of active Associates and Preferred Customers in these markets. Additionally, sales in our newest market Colombia, which commenced operations in the third quarter of 2013, increased by \$1.1 million for the nine month period.

*Asia Pacific:* The increase in net sales in this region was primarily the result of an increase in the average number of active Associates.

Table of Contents

The increase in Southeast Asia Pacific was driven by sales growth in every market within this region despite a \$4.8 million reduction from changes in currency exchange rates. The strongest growth in this region came from the Philippines and Singapore, where net sales increased 23.0% and 21.1%, respectively. Sales in Singapore benefited from a year-over-year increase in sales of our MyHealthPak product to our Associates in other Asia Pacific markets.

Sales in Australia and New Zealand during the first nine months of 2014 increased 4.6% despite a \$1.7 million reduction from changes in currency exchange rates. On a local currency basis, net sales in this market increased 9.0%.

The increase in net sales in Greater China included a 110.2% increase in net sales in mainland China, offset in great part by a large decrease in Hong Kong despite the recognition of \$3.1 million of previously unearned revenue discussed above. Notably, the decrease in Hong Kong includes an estimated \$7.0 million in incremental sales generated ahead of a worldwide policy that we implemented during the second quarter of 2013 (restricting Associate purchases to in-market purchases only), which makes for a difficult year-over-year comparable.

The increase in net sales in North Asia resulted from a 19.5% increase in net sales in South Korea, which was driven by an increase in the number of active Associates in that market.

*Gross Profit*

Gross profit declined to 81.6% of net sales for the first nine months of 2014, compared with 82.4% in the prior year period. This decline can be attributed to unfavorable currency fluctuations, price discounts, and an increase in relative freight costs. This decrease was partially offset by annual price changes and favorable changes in product and market mix.

*Associate Incentives*

Associate incentives increased to 43.1% of net sales for the first nine months of 2014, from 42.1% in the prior year period. This increase was the result of the 2013 strategic changes, partially offset by annual pricing changes.

*Selling, General and Administrative Expenses*

Relative to net sales, our selling, general and administrative expense was flat when compared with the first nine months of 2013 due to leverage gained on a higher sales base. In absolute terms, our selling, general and administrative expense increased by \$6.8 million. This increase was primarily driven by higher wages and benefits expense and other costs associated with supporting a higher sales base.



*Income Taxes*

Our effective income tax rate during the first nine months of 2014 was 33.8%, compared with 33.0% in same period of 2013. This increase was primarily the result of a reduction in our United States manufacturing deduction benefit due to increased sales in China where products are manufactured locally, and a reduction in tax benefits from lower tax rate jurisdictions, where sales decreased. The increase in our effective tax rate was partially offset by a lower state tax expense.

*Net Earnings and Diluted Earnings Per Share*

Net earnings for the first nine months of 2014 decreased 5.8% when compared with the first nine months of 2013. This decrease was due to a combination of higher relative Associate incentives expense and lower gross profit as discussed above. Partially offsetting this decrease was the \$1.4 million benefit from the recognition of deferred revenue.

Diluted earnings per share decreased 4.8% in the first nine months of 2014 when compared with the prior year period due to reduced net earnings. This decrease was offset slightly by a lower number of diluted shares outstanding resulting from share repurchases over the last twelve months. Without the recognition of deferred revenue, diluted earnings per share would have declined 7.2%

Table of Contents

**Liquidity and Capital Resources**

We have historically met our working capital and capital expenditure requirements by using both net cash flow from operations and by drawing on our line of credit. Our principal source of liquidity is our operating cash flow. Although we are required to maintain cash deposits with banks in some of our markets, there are currently no material restrictions on our ability to transfer and remit funds among our international markets. The hypothetical repatriation of \$13.2 million that relates to earnings considered indefinitely reinvested in certain of our markets at September 27, 2014, would result in a tax liability to the Company of approximately \$1.7 million.

We have historically generated positive cash flow due to our strong operating margins. Net cash flow from operating activities totaled \$67.4 million in the first nine months of 2014, compared with \$64.6 million in the first nine months of 2013. Items positively affecting cash flow from operations on a year-over-year basis include: (i) a reduction in inventory in the current year, compared with use of cash in the prior year to build up inventory for various reasons, including the launch of a new market, and (ii) timing of tax payments associated with higher benefits derived from exercise of equity awards in the prior year period. These items were partially offset by (i) a larger increase in other liabilities in the prior year period due to higher accruals, (ii) a decrease in accounts payable in the current year period, compared with an increase in the prior year period, and (iii) lower net earnings in the current year period.

Although we generated strong cash flow from operating activities in the first nine months of 2014, cash and cash equivalents decreased to \$87.7 million at September 27, 2014, from \$137.3 million at December 29, 2013. This decrease in cash and cash equivalents was primarily due to share repurchases as discussed below, and purchases of property, plant, and equipment related mostly to the construction of our new China production facility also discussed below. Of the \$87.7 million cash and cash equivalents held at September 27, 2014, \$14.2 million was held in the United States and \$73.5 million was held by international subsidiaries. Of the \$137.3 million held at December 28, 2013, \$65.8 million was held in the United States and \$71.5 million was held by international subsidiaries. Net working capital decreased to \$57.0 million at September 27, 2014, from \$133.2 million at December 28, 2013.

We are building a state-of-the-art manufacturing and production facility in China, which we anticipate will become operational during the latter half of 2015. We anticipate that this project will require a total investment of approximately \$40 million, of which approximately \$24 million will be incurred in 2014. During the first nine months of 2014, we incurred \$12.9 million on this project of which \$5.9 million was for land use rights.

We have extended non-revolving credit to the supplier of our nutrition bars to allow this supplier to acquire the necessary equipment to manufacture our bars. Notes receivable from this supplier as of September 27, 2014, were \$7.4 million and are included as non-current other assets on the balance sheet. We are in the process of evaluating options to potentially modify some of the terms of the credit agreement with this supplier as there has been a delay in the completion of the project. As a result of the delays, we performed an impairment test on the recoverability of this note receivable and concluded that there was no impairment as of September 27, 2014, however, if assumptions change in the future, impairment could result. We will evaluate this note receivable for impairment on an ongoing basis.

*Line of credit*

## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

We have a long-standing relationship with Bank of America. We currently maintain a \$75.0 million credit facility pursuant to a credit agreement with the bank, which expires in April 2016. Bank guarantees are considered a reduction of the overall availability of credit. As of September 27, 2014, such normal course of business bank guarantees reduced our available borrowing limit by \$4.7 million. During the quarter, we utilized our credit facility and as of September 27, 2014 we had a balance of \$10.0 million outstanding.

The agreement for this credit facility contains restrictive covenants, which require us to maintain a consolidated rolling four-quarter adjusted earnings before interest, taxes, depreciation and amortization ( adjusted EBITDA ) equal to or greater than \$60.0 million, and a ratio of consolidated funded debt to adjusted EBITDA of 2.0 to 1.0 at the end of each quarter. The adjusted EBITDA under this agreement is modified for certain non-cash expenses. As of September 27, 2014, we were in compliance with these covenants. Management is not aware of any issues currently impacting Bank of America's ability to honor their commitment to extend credit under this facility.

Table of Contents

*Share repurchase*

We have a share repurchase plan that has been ongoing since the fourth quarter of 2000. The objective of this plan is to return value to our shareholders. Our Board of Directors has periodically approved additional dollar amounts for share repurchases under that plan. Share repurchases are made from time-to-time, in the open market, through block trades or otherwise, and are based on market conditions, the level of our cash balances, general business opportunities, and other factors. During the second quarter of 2014, our Board of Directors authorized an increase in the amount available for repurchase under this plan to a total of \$200 million. During the nine months ended September 27, 2014, we repurchased and retired 1,755,001 shares of common stock for a total investment of \$125.7 million, at an average market price of \$71.6 per share. Additionally, subsequent to the quarter ended September 27, 2014, and through November 3, 2014, we repurchased and retired 171,924 shares of common stock for a total investment of \$13.2 million, at an average market price of \$76.59 per share pursuant to a preset trading plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934 as amended. As of November 3, 2014, there was \$61.2 million remaining under the current share repurchase authorization and there is currently no expiration date on the remaining approved repurchase amount and no requirement for future share repurchases.

*Summary*

We believe that current cash balances, future cash provided by operations, and amounts available under our line of credit will be sufficient to cover our operating and capital needs in the ordinary course of business for the foreseeable future. If we experience an adverse operating environment or unanticipated and unusual capital expenditure requirements, additional financing may be required. No assurance can be given, however, that additional financing, if required, would be available or on favorable terms. We might also require or seek additional financing for the purpose of expanding into new markets, growing our existing markets, or for other reasons. Such financing may include the use of additional debt or the sale of additional equity securities. Any financing which involves the sale of equity securities or instruments that are convertible into equity securities could result in immediate and possibly significant dilution to our existing shareholders.

**Forward-Looking Statements and Certain Risks**

The statements contained in this report that are not purely historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. These statements represent our expectations, hopes, beliefs, anticipations, commitments, intentions, and strategies regarding the future. They may be identified by the use of words or phrases such as believes, expects, anticipates, should, plans, estimates, and potential, among others. Forward-looking statements include, but are not limited to, statements contained in Management's Discussion and Analysis of Financial Condition and Results of Operations regarding our financial performance, revenue, and expense levels in the future and the sufficiency of our existing assets to fund our future operations and capital spending needs. Readers are cautioned that actual results could differ materially from the anticipated results or other expectations that are expressed in these forward-looking statements for the reasons that are detailed in our most recent Annual Report on Form 10-K. The fact that some of these risk factors may be the same or similar to those in our past SEC reports means only that the risks are present in multiple periods. We believe that many of the risks detailed here and in our other SEC filings are part of doing business in the industry in which we operate and will likely be present in all periods reported. The fact that certain risks are common in the industry does not lessen their significance. The forward-looking statements contained in this report are made as of the date of this report, and we assume no obligation to update them or to update the reasons why our actual results could differ from those that we have projected. Among others, risks and uncertainties that may affect our business, financial condition, performance, development, and results of operations include:

- Our ability to attract and maintain a sufficient number of Associates;

- Our dependence upon a network marketing system to distribute our products and the activities of our independent Associates;
- The integration of BabyCare's operations and expansion of our business in China through BabyCare;
- Unanticipated effects of changes to our Compensation Plan;

Table of Contents

- Our planned expansion into international markets, including delays in commencement of sales or product offerings in any new market, delays in compliance with local marketing or other regulatory requirements, or changes in target markets;
- General economic conditions, both domestically and internationally;
- Potential political events, natural disasters, or other events that may negatively affect economic conditions;
- Potential effects of adverse publicity regarding the Company, nutritional supplements, or the network marketing industry;
- Reliance on key management personnel;
- Extensive government regulation of the Company's products, manufacturing, and network marketing system;
- Potential inability to sustain or manage growth, including the failure to continue to develop new products;
- An increase in the amount of Associate incentives;
- Our reliance on the use of information technology;
- The effects of competition from new and established network and direct selling organizations in our key markets;
- The adverse effect of the loss of a high-level sponsoring Associate, together with a group of leading Associates, in that person's downline;
- The loss of product market share or Associates to competitors;

## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

- Potential adverse effects of customs, duties, taxation, and transfer pricing regulations, including regulations governing distinctions between and Company responsibilities to employees and independent contractors;
- The fluctuation in the value of foreign currencies against the U.S. dollar;
- Our reliance on outside suppliers for raw materials and certain manufactured items;
- Shortages of raw materials that we use in certain of our products;
- Significant price increases of our key raw materials;
- Product liability claims and other risks that may arise with our manufacturing activity;
- Intellectual property risks;
- Liability claims that may arise with our Athlete Guarantee program;
- Continued compliance with debt covenants;
- Disruptions to shipping channels that are used to distribute our products to international warehouses;
- The introduction of new laws or changes to existing laws, both domestically and internationally; or
- The outcome of regulatory and litigation matters.

### **Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

There have been no material changes to information presented from that presented for the year ended December 28, 2013.



Table of Contents

**Item 4. CONTROLS AND PROCEDURES**

**Disclosure Controls and Procedures**

We maintain disclosure controls and procedures that are designed to ensure that information that is required to be disclosed in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods that are specified in the SEC's rules and forms and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding any required disclosure. In designing and evaluating these disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

As of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Based on this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 27, 2014.

**Changes in Internal Control Over Financial Reporting**

There were no changes in our internal control over financial reporting that occurred during the quarter ended September 27, 2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

**PART II. OTHER INFORMATION**

**Item 1. LEGAL PROCEEDINGS**

Rawcliffe on behalf of USANA Health Sciences, Inc. v. Certain Directors and Officers of USANA

On August 7, 2014, a purported shareholder derivative lawsuit was filed in the Third Judicial District Court of Salt Lake County, State of Utah, against certain of our directors and officers. The derivative complaint, which also names USANA as a nominal defendant but is asserted on USANA's behalf, contains claims of breach of fiduciary duty, waste of corporate assets and unjust enrichment against the defendant directors and officers in connection with certain equity awards granted by the Compensation Committee of the Company's Board of Directors in February 2014. The complaint purports to seek, on behalf of the Company, an unspecified amount of monetary damages allegedly sustained by the Company, rescission or disgorgement of the applicable equity awards, unspecified equity relief, reimbursement for fees and costs incurred by the plaintiff in connection with the suit, including attorneys' fees, and various other forms of monetary and non-monetary relief. We believe the claims in the complaint are without merit and intend to vigorously defend the suit. Consequently, on October 2, 2014, we filed a motion to dismiss the complaint and are awaiting the court's ruling on the motion. Based on the information currently available, we currently believe that the final outcome of this suit will not have a material adverse effect on the Company's business, results of operations or consolidated financial position.

See also our discussion under Note H, Contingencies, to the Condensed Consolidated Financial Statements included in Item 1 of Part I of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

Table of Contents**Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

## (c) Repurchases

The following table presents information with respect to purchases of USANA common stock made by the Company during the three months ended September 27, 2014:

**Issuer Purchases of Equity Securities**

(amounts in thousands, except per share data)

<b>Period</b>	<b>Total Number of Shares Purchased</b>	<b>Average Price Paid per Share</b>	<b>Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</b>	<b>Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs *</b>
Fiscal July (Jun. 29, 2014 through Aug. 2, 2014)	430	\$ 71.97	430	\$ 119,953
Fiscal August (Aug. 3, 2014 through Aug. 30, 2014)	380	\$ 70.09	380	\$ 93,275
Fiscal September (Aug. 31, 2014 through Sep. 27, 2014)	263	\$ 72.00	263	\$ 74,348
	1,073	\$ 71.31	1,073	

\* The Company's share repurchase plan has been ongoing since the fourth quarter of 2000, with the Company's Board of Directors periodically approving additional dollar amounts for share repurchases under the plan. The Company began the third quarter of 2014 with \$150,905 remaining under the plan. Subsequent to the quarter ended September 27, 2014, and through November 3, 2014, the Company repurchased 172 shares for a total of \$13,167, at an average market price of \$76.59 per share pursuant to a Rule 10b5-1 trading plan. As of November 3, 2014, the Company had \$61,181 available under the share repurchase plan. There currently is no expiration date on the approved repurchase amount.

Table of Contents

**Item 6. EXHIBITS**

Exhibit Number	Description
3.1	Amended and Restated Articles of Incorporation (Incorporated by reference to Report on Form 8-K, filed April 25, 2006)
3.2	Bylaws (Incorporated by reference to Report on Form 8-K, filed April 25, 2006)
4.1	Specimen Stock Certificate for Common Stock, no par value (Incorporated by reference to Registration Statement on Form 10, File No. 0-21116, effective April 16, 1993)
10.1	2002 USANA Health Sciences, Inc. Stock Option Plan (Incorporated by reference to Registration Statement on Form S-8, filed July 18, 2002)*
10.2	Form of employee or director non-statutory stock option agreement under the 2002 Stock Option Plan (Incorporated by reference to Report on Form 10-K, filed March 6, 2006)*
10.3	Form of employee incentive stock option agreement under the 2002 Stock Option Plan (Incorporated by reference to Report on Form 10-K, filed March 6, 2006)*
10.4	Credit Agreement, dated June 16, 2004, by and between Bank of America, N.A. and USANA Health Sciences, Inc. (Incorporated by reference to Report on Form 10-Q for the period ended July 3, 2004)
10.5	Amendment dated May 17, 2006 to Credit Agreement dated June 16, 2004 (Incorporated by reference to Report on Form 10-Q for the period ended September 30, 2006)
10.6	Amendment dated April 24, 2007 to Credit Agreement dated June 16, 2004 (Incorporated by reference to Report on Form 10-Q for the period ended March 31, 2007)
10.7	USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 25, 2006)*
10.8	Form of Stock Option Agreement for award of non-statutory stock options to employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*
10.9	Form of Stock Option Agreement for award of non-statutory stock options to directors who are not employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*
10.10	Form of Incentive Stock Option Agreement for employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*
10.11	Form of Stock-Settled Stock Appreciation Rights Award Agreement for employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*
10.12	Form of Stock-Settled Stock Appreciation Rights Award Agreement for directors who are not employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*
10.13	Form of Deferred Stock Unit Award Agreement for grants of deferred stock units to directors who are not employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (Incorporated by reference to Report on Form 8-K, filed April 26, 2006)*



## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

### Table of Contents

10.14	Form of Indemnification Agreement between the Company and its directors (Incorporated by reference to Report on Form 8-K, filed May 24, 2006)*
10.15	Form of Indemnification Agreement between the Company and certain of its officers (Incorporated by reference to Report on Form 8-K, filed May 24, 2006)*
10.16	Share Purchase Agreement, dated as of August 16, 2010, among USANA Health Sciences, Inc., Petlane, Inc., Yaolan Ltd., and BabyCare Holdings Ltd. (Incorporated by Reference to Report on Form 8-K, filed August 16, 2010)
10.17	Amended and Restated Credit Agreement, dated as of April 27, 2011 (Incorporated by reference to Report on Form 8-K, filed April 28, 2011)
10.18	Form of Executive Confidentiality, Non-Disclosure and Non-Solicitation Agreement (Incorporated by reference to Quarterly Report on Form 10-Q for the period ended October 1, 2011, filed November 9, 2011)*
10.19	Separation and Release of Claims Agreement dated as of December 21, 2012 by and between USANA Health Sciences, Inc. and Roy Truett (incorporated by reference to Report on Form 8-K/A, filed December 26, 2012)*
10.20	Amendment to Confidentiality, Non-Disclosure and Non-Solicitation Agreement dated as of December 21, 2012 by and between USANA Health Sciences, Inc. and Roy Truett (incorporated by reference to Report on Form 8-K/A, filed December 26, 2012)*
10.21	Amendment to Amended and Restated Credit Agreement, dated as of July 18, 2013 (Incorporated by reference to Report on Form 8-K, filed July 23, 2013)
31.1	Certification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350
32.2	Certification of Chief Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

---

\* Denotes a management contract or compensatory plan or arrangement.

Table of Contents

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

USANA HEALTH SCIENCES, INC.

Date: November 6, 2014

/s/ Paul A. Jones  
Paul A. Jones  
Chief Financial Officer

(Principal Financial and Accounting Officer)